🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being described as a "major milestone" in the fight against increasingly resistant strains of the bacteria, according to researchers.

An International Health Concern

Cases of gonorrhoea are increasing around the world, with figures suggesting more than 82 million infections annually. Notably increased rates are observed in the African continent and nations within the WHO's designated area, which includes China and Mongolia to New Zealand. Within England, cases have hit a record high, while figures across Europe in 2023 were significantly elevated compared to those in 2014.

“The authorization of new treatments for gonorrhoea is an important and timely development in the context of growing infection rates, increasing antimicrobial resistance and the extremely scarce therapeutic options presently on offer.”

Public health authorities are increasingly worried about the increase in drug-resistant strains. The World Health Organization has classified it as a "critical concern". Recent surveillance revealed that resistance to standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Drugs Secure Approval

Zoliflodacin, marketed under the name Nuzolvence, was approved by the US FDA in recent days for treating gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Scientists hope that specific application of this new drug will help slow the emergence of superbugs.

Gepotidacin, originating from the pharmaceutical company GSK, was also approved in the same week. This treatment, which is additionally indicated for UTIs, was proven in research to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin emerged from a new, not-for-profit approach for medication research. The non-profit organisation GARDP partnered with the pharmaceutical company Innoviva to see it through.

“This approval represents a major breakthrough in the management of highly resistant gonorrhoea, which previously has been evolving faster than antibiotic development.”

Research Study Outcomes and Worldwide Availability

According to data published in a major medical journal, zoliflodacin cured the vast majority of uncomplicated infections. This places it at an comparable level with the existing first-line therapy, which uses a dual-drug approach. The study enrolled over 900 patients from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, the non-profit has the authority to license and sell the drug in many developing nations.

Clinicians on the front lines have expressed hope. Access to a single-dose, oral treatment of this kind is hailed as a "revolutionary step" for public health efforts. This is viewed as vital to alleviate the strain of the infection for individuals and to stop the proliferation of extremely resistant gonorrhoea around the world.